INOZYME PHARMA, INC.

2023 ANNUAL MEETING OF STOCKHOLDERS

RULES OF CONDUCT

Welcome to the 2023 Annual Meeting of Stockholders (the "Meeting") of Inozyme Pharma, Inc. (the "Company"). We are holding the meeting in an all-virtual format. In fairness to all persons participating in the Meeting, in order to provide stockholders an opportunity to be heard, and in the interest of conducting an orderly meeting within a reasonable time period, we will be observing the following rules of conduct:

- 1. **Participation.** Only stockholders of record at the close of business on April 17, 2023, or their duly authorized proxies, are entitled to vote and submit questions at the Meeting. To vote or submit questions, please log into the virtual meeting platform (the "Virtual Meeting Website") by using the unique link provided to you via email granting you access to the Meeting.
- 2. **Order of Business.** The only business to be conducted at the Meeting are the proposals set forth in the Notice of 2023 Annual Meeting of Stockholders (the "Notice of Meeting") and in the Proxy Statement. The business of the Meeting will follow the order shown in the Notice of Meeting.
- 3. Chair of the Meeting. The Company's Chief Executive Officer and Chairman of the Board of Directors shall be the chair of the Meeting (the "Chair") and may make any and all determinations as to the conduct of the Meeting and the procedures to be followed during the Meeting, including these rules of conduct.
- 4. **Voting.** You do not need to vote at the Meeting if you have already voted in advance of the Meeting. However, if you wish to change your vote, or if you have not previously voted, you may vote online during the Meeting while the polls are open. The polls will close promptly following the presentation of the last agenda item being voted on.
- 5. **Questions.** Stockholders will have the opportunity to submit questions prior to and during the Meeting. Please submit any questions before the start time of the Meeting.
 - a. If you are a stockholder and wish to submit a question, you may do so during the registration process for the Meeting and beginning at 9:45 a.m., Eastern Time, on June 13, 2023, you may log into the Virtual Meeting Website by using the unique link provided to you via email one hour prior to the start of Meeting and follow the instructions there.
 - b. If you are a stockholder and wish to submit a question about one of the matters being voted on at the Meeting, the question can be submitted online at the Virtual Meeting Website at or before the time the matters are before the Meeting for consideration. We will answer appropriate questions regarding matters voted on at the Meeting before voting is closed.
 - c. To allow the Company time to answer questions from as many stockholders as possible, we will limit each stockholder to two questions. A question should be succinct and should cover only one topic. Questions from multiple stockholders on the same topic or that are otherwise related may be grouped, summarized, and answered together.
 - d. When submitting a question, you are required to provide your name and your relationship to the Company.

- e. Because time is limited at the Meeting, we may not be able to answer all questions that are submitted. If there are any questions that are not answered, such questions can be raised separately after the Meeting by contacting Investor Relations at ir@inozyme.com.
- f. Questions or comments unrelated to the Meeting or of individual concerns rather than of general concern to all stockholders may be submitted by contacting Investor Relations at ir@inozyme.com.
- g. The Company does not intend to answer questions that are, among other things:
 - i. irrelevant to the business of the Company or the business of the Meeting;
 - ii. related to material non-public information of the Company;
 - iii. related to personal grievances;
 - iv. derogatory references to individuals or that are otherwise in bad taste;
 - v. related to threatened or ongoing litigation;
 - vi. repetitious statements already made by another stockholder;
 - vii. a matter of individual concern that is not a matter of interest to stockholders generally; or
 - viii. out of order or not otherwise suitable for the conduct of the Meeting as determined by the Chair or our Corporate Secretary in their reasonable judgment.

6. Issues During the Meeting.

- a. If you encounter any difficulties accessing the Meeting during the check-in or meeting time, please contact technical support, whose contact information will be included in the email containing the unique link granting access to the Meeting.
- b. In the event of disorder, technical malfunction, or other significant problem that disrupts the Meeting, the Chair may adjourn, recess or expedite the Meeting or take such other action that the Chair determines is appropriate in light of the circumstances.
- 7. **Recording.** Any recording of the Meeting is prohibited.

Thank you in advance for your cooperation and thank you for your continued interest in Inozyme Pharma, Inc.